![S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-21634-1/MediaObjects/41467_2021_21634_Fig1_HTML.png)
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications
![Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/32b4f7f5-a2ff-459c-9431-ea13860d3d0f/gr3_lrg.jpg)
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
![CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure – CEPI CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure – CEPI](https://cepi.net/wp-content/uploads/2020/11/IMAGE-CLOVER-EXPANDED-PARTNERSHIP.jpg)
CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure – CEPI
![Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August | Fierce Biotech Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August | Fierce Biotech](https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1592558011/GettyImages-1205778418.jpg/GettyImages-1205778418.jpg?VersionId=cVldy8UTtGk_CWImi2SZLY3Zmjud_scK)
Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August | Fierce Biotech
Fierce Pharma Asia—WuXi-BMS plant deal; Clover-GSK COVID-19 vax pact ends; Illumina-Sequoia genomics incubator | Fierce Pharma
![S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-021-21634-1/MediaObjects/41467_2021_21634_Fig5_HTML.png)
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications
![Drug Discovery News on Twitter: "#Dynavax to provide #TLR9 agonist #adjuvant CpG 1018 to help #Clover #Biopharma evaluate its #COVID19 #vaccine lead #Coronavirus S-trimer subunit vaccine developed using Clover's Trimer-Tag platform https://t.co ... Drug Discovery News on Twitter: "#Dynavax to provide #TLR9 agonist #adjuvant CpG 1018 to help #Clover #Biopharma evaluate its #COVID19 #vaccine lead #Coronavirus S-trimer subunit vaccine developed using Clover's Trimer-Tag platform https://t.co ...](https://pbs.twimg.com/media/ET4yXn1WAAAfEw4.jpg)
Drug Discovery News on Twitter: "#Dynavax to provide #TLR9 agonist #adjuvant CpG 1018 to help #Clover #Biopharma evaluate its #COVID19 #vaccine lead #Coronavirus S-trimer subunit vaccine developed using Clover's Trimer-Tag platform https://t.co ...
![Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients | Business Wire Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients | Business Wire](https://mms.businesswire.com/media/20200210005300/en/758310/23/Clover_Logo-New_vEnglish.jpg)
Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients | Business Wire
![Clover Biopharmaceuticals Becomes the 9th Enterprise in CDHT Listed on the Hong Kong Stock Exchange_News_GaoxinEnglish Clover Biopharmaceuticals Becomes the 9th Enterprise in CDHT Listed on the Hong Kong Stock Exchange_News_GaoxinEnglish](http://www.cdht.gov.cn/gaoxin/c141902/2021-12/20/edd6142c27ac45289add7fcc8092cf5c/images/d3c498cd9ebe4768b03dc70ed679cd6c.jpg)